Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Calgary

$96,580.00

Immunoregulatory nanovaccines: Optimization of physical, chemical, pharmacokinetic and immunological properties for bench-to-bedside translation

FY 2013-14

Summary
The current proposal is founded on the discovery of a new paradigm in the treatment of type 1 diabetes (causedby the white blood cells of the immune system) of potential groundbreaking significance. Traditionally,vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria orcancer, or to delete white blood cells capable of causing autoimmune diseases (such as T1D). We havedeveloped a 'vaccine' that can cure diabetes by selectively expanding what we call 'autoregulatory' white bloodcells. These constitute a new type of 'autoreactive' white blood cells (like their diabetes-causing counterparts,they specifically recognize pancreatic ß-cells) whose function is to put the brakes on the diabetes-causingautoimmune attack. These cells become activated when they sense the attack on the pancreas and engage into acompetitive tug-of-war with the ß-cell killer white blood cells, often unsuccessfully. Our vaccine can expandthis population of white blood cells, enhancing their diabetes-countering effects. This vaccine can blunt diseaseprogression in pre-diabetic animals and restore normal blood sugar levels in diabetic mice without causinggeneralized suppression of the immune system.The current vaccine platform is based on tiny particles of a metal (many times smaller than a cell; also referredto as nanoparticles -NP-) coated with antigenic targets of beta cell-killer white blood cells (pMHC-coated NPs).The objective of this proposal is to synthesize optimized clinical-grade pMHC-coated NPs to maximizetherapeutic efficacy while reducing the potential for toxicity. This work, which will be done by aninterdisciplinary team of established scientists and trainees spanning the spectrum of nanotechnology,biochemistry, immunology and autoimmune disease will pave the way for human clinical trials.
Program
Collaborative Health Research Projects
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
397565-2011
Name nom
Santamaria, Pere
Department département
Microbiology and Infectious Diseases
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2011
Award amount
96580
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
3
Nb partie
3
Application title
Immunoregulatory nanovaccines: Optimization of physical, chemical, pharmacokinetic and immunological properties for bench-to-bedside translation
Keyword
NSERC
Application summary
The current proposal is founded on the discovery of a new paradigm in the treatment of type 1 diabetes (causedby the white blood cells of the immune system) of potential groundbreaking significance. Traditionally,vaccines have been used to expand white blood cells capable of affording protection against viruses, bacteria orcancer, or to delete white blood cells capable of causing autoimmune diseases (such as T1D). We havedeveloped a 'vaccine' that can cure diabetes by selectively expanding what we call 'autoregulatory' white bloodcells. These constitute a new type of 'autoreactive' white blood cells (like their diabetes-causing counterparts,they specifically recognize pancreatic ß-cells) whose function is to put the brakes on the diabetes-causingautoimmune attack. These cells become activated when they sense the attack on the pancreas and engage into acompetitive tug-of-war with the ß-cell killer white blood cells, often unsuccessfully. Our vaccine can expandthis population of white blood cells, enhancing their diabetes-countering effects. This vaccine can blunt diseaseprogression in pre-diabetic animals and restore normal blood sugar levels in diabetic mice without causinggeneralized suppression of the immune system.The current vaccine platform is based on tiny particles of a metal (many times smaller than a cell; also referredto as nanoparticles -NP-) coated with antigenic targets of beta cell-killer white blood cells (pMHC-coated NPs).The objective of this proposal is to synthesize optimized clinical-grade pMHC-coated NPs to maximizetherapeutic efficacy while reducing the potential for toxicity. This work, which will be done by aninterdisciplinary team of established scientists and trainees spanning the spectrum of nanotechnology,biochemistry, immunology and autoimmune disease will pave the way for human clinical trials.
University of Calgary - $96,580 Grant (2013-14) | Canada Spends